Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 580Neoplasms 488Prostatic Neoplasms 311Lung Neoplasms 236Colorectal Neoplasms 199Motor Activity 131Carcinoma, Non-Small-Cell Lung 117Uterine Cervical Neoplasms 112Brain Neoplasms 110Pancreatic Neoplasms 109Head and Neck Neoplasms 106Stomach Neoplasms 99Carcinoma, Hepatocellular 98Rectal Neoplasms 97Ovarian Neoplasms 86Colonic Neoplasms 86Neoplasm Metastasis 67Multiple Myeloma 65Esophageal Neoplasms 65Hematologic Neoplasms 62Urinary Bladder Neoplasms 60Glioblastoma 59Melanoma 58Sarcoma 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Endometrial Neoplasms 56Glioma 53Lymphoma 50Leukemia, Myeloid, Acute 48Gastrointestinal Neoplasms 48

Interventions

Dipyrone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Hemostatic Disorders × Clear all
NCT07384013 2026-02-03

Study Protocol: Impact of Metamizole (OptalginĀ®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

Rambam Health Care Campus

Phase NA Recruiting
30 enrolled

Agnosia, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚔